Piper Jaffray Companies began coverage on shares of Health Catalyst (NASDAQ:HCAT) in a research note published on Monday morning, BenzingaRatingsTable reports. The firm issued an overweight rating and a $47.00 target price on the stock.
Several other equities research analysts also recently issued reports on the company. William Blair initiated coverage on Health Catalyst in a report on Monday. They set an outperform rating for the company. Leerink Swann initiated coverage on Health Catalyst in a report on Monday. They set an outperform rating and a $55.00 price target for the company. Evercore ISI initiated coverage on Health Catalyst in a report on Monday. They set an outperform rating and a $50.00 price target for the company. Finally, SunTrust Banks initiated coverage on Health Catalyst in a report on Monday. They set a buy rating and a $53.00 price target for the company. Eight research analysts have rated the stock with a buy rating, Health Catalyst presently has a consensus rating of Buy and an average price target of $51.29.
NASDAQ HCAT opened at $43.66 on Monday. Health Catalyst has a 52 week low of $36.29 and a 52 week high of $49.85.
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its products include analytics platform, accountable care and financial, benchmarking and comparative analytics, care management and population health, clinical analytics, operations and performance management, patient safety, and services.
Featured Article: What strategies should day traders use to execute a trade?
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.